Trial · NCT04069156
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Powered Primary Endpoint of Survival Free of Non-surgical Major Hemocompatibility Related Adverse Events | 12 Months | The primary end point was analyzed in the principal analysis population, which excluded patients with events occurring within 14 days after LVAD implantation to avoid counting surgical complications not attributed to the treatment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Rates of Non-surgical Major Hemorrhagic Events | Through Study Completion with a Median Follow up of 14 Months | Modified Intention to Treat Population (mITT) | Event Per 100 Patient-Year | NUMBER |
| SECONDARY | Rates of Bleeding Events | Through Study Completion with a Median Follow up of 14 Months | Modified Intention to Treat Population (mITT) | Event Per 100 Patient-Year | NUMBER |
| SECONDARY | Rates of Non-surgical Major Thrombotic Events | Through Study Completion with a Median Follow up of 14 Months | Modified Intention to Treat Population (mITT) | Event Per 100 Patient-Year | NUMBER |
| SECONDARY | Rates of Stroke | Through Study Completion with a Median Follow up of 14 Months | Modified Intention to Treat Population (mITT) | Event Per 100 Patient-Year | NUMBER |
| SECONDARY | Survival Rates | 24 Months | Modified Intention to Treat Population (mITT) | Percentage of Participants | NUMBER |
| SECONDARY | Risk of Non-Surgical Bleeding Events | 24 Months | Modified Intention to Treat Population | Percentage of Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Rate of Rehospitalization | Through Study Completion with a Median Follow up of 14 Months | Modified Intention to Treat Population | Event Per 100 Patient-Year | NUMBER |
| OTHER_PRE_SPECIFIED | Economic Cost Implications - Total Estimated Cost for Bleeding Events (CMS Cost Basis) | 12 Months | Only US subjects were included in this analysis | USD | NUMBER |
| OTHER_PRE_SPECIFIED | Economic Cost Implications - Average Cost Per Bleeding Event | 12 Months | Only US subjects were included in this analysis | USD | NUMBER |
| OTHER_PRE_SPECIFIED | Economic Cost Implications - Average Cost Per Study Patient Over the First-year Post-implant | 12 Months | Only US subjects were included in this analysis | USD | NUMBER |
| OTHER_PRE_SPECIFIED | Economic Cost Implications - Cost of Bleeding Hospitalization for 1000 LVAD Implants Over the First-year Post-implant | 12 Months | Only US subjects were included in this analysis | USD/1000 implants/1 year | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04069156/outcomes